# Mathematical modelling of SARS-CoV-2: Alpha variant (B.1.1.7)

Nick Davies



6 July, 2023

### Emergence of the Alpha variant...







0.00 0.25 0.50 0.75 1.00 Frequency of S gene target failure





Frequency of S gene target failure



SEIR-type model, age-stratified Two strains

Age group *i*:  $\lambda_i$  = force of infection  $u_i$  = susceptibility  $y_i$  = clinical fraction



### Table S3.

Model parameters not subject to fitting.

Parameter	Description	Value	Notes
de	Latent period (E to $I_P$ , E to $I_S$ , L to $I_S$ ; days)	~gamma(µ = 2.5, <i>k</i> = 2.5)	Set to 2.5 so that incubation period (latent period plus period of preclinical infectiousness) is 5 days(70)
d₽	Duration of preclinical infectiousness (I <sub>P</sub> to I <sub>c</sub> ; days)	~gamma(µ = 2.5, <i>k</i> = 4)	Assumed to be half the duration of total infectiousness in clinically-infected individuals ( <i>14</i> )
<b>d</b> c	Duration of clinical infectiousness (I <sub>c</sub> to R; days)	~gamma(µ = 2.5, <i>k</i> = 4)	Infectious period set to 5 days, to result in a serial interval of approximately 6 days(71–73)
ds	Duration of subclinical infectiousness (I <sub>S</sub> to R; days)	~gamma(µ = 5.0, <i>k</i> = 4)	Assumed to be the same duration as total infectious period for clinical cases, including preclinical transmission
<b>y</b> i	Probability of clinical symptoms given infection for age group <i>i</i>	Estimated from case distributions across 6 countries	(19)
f	Relative infectiousness of subclinical cases	50%	Assumed (15, 19)
Ci.j	Number of age- <i>j</i> individuals contacted by an age- <i>i</i> individual per day, prior to changes in mobility	UK-specific contact matrix	(74)



## Age-specific clinical fraction & susceptibility





Using contact matrices specific to each of the 32 regions, calculated the expected distribution of infections given a candidate age-specific profile of susceptibility and symptom severity.



#### Table S3.

### Model parameters not subject to fitting.

Parameter	Description	Value	Notes
Ni	Number of age- <i>i</i> individuals	From demographic data	(75)
$\Delta t$	Time step for discrete-time simulation	0.25 days	
P(ICU)i	Proportion of hospitalised cases that require critical care for age group <i>i</i>	Estimated from CO-CIN data	(66)
Ws	Waning rate of seropositivity	224 days <sup>.1</sup>	Estimated from serology data
<i>los</i> hosp	Length of stay in hospital	~lognormal(µ <sub>log</sub> = 11.08, sd <sub>log</sub> = 1.20)	Estimated from CO-CIN data (66)
los <sub>icu</sub>	Length of stay in ICU	~lognormal(µ <sub>log</sub> = 13.33, sd <sub>log</sub> = 1.25)	Estimated from CO-CIN data (66)
detect <sub>0</sub> , detect <sub>1</sub> , detect <sub>s0</sub> , detect <sub>s1</sub>	Delay from hospital admission to SARS- CoV-2 test	$detect_0 = 14$ $detect_1 = 1$ $detect_{s0} = 5.86$ $detect_{s1} = 33.4$	To capture substantial delays in testing at the beginning of the epidemic in the UK, we assume that the delay from hospital admission to confirmed SARS-CoV-2 infection is $asc(t/366, detect_0, detect_1, detect_{s0}, detect_{s1})$ , where <i>t</i> is time in days since 1 January 2020. Estimated from a previous round of model fitting.

LONDON SCHOOL of HYGIENE &TROPICAL MEDICINE



# **Table S2.**Details of fitted parameters.

Parameter	Description	Prior distribution	Notes
tS	Start date of epidemic in days after 1 January 2020	~uniform(0, 60)	Determines date at which seeding begins in region; starting on this date, one random individual per day contracts SARS-CoV-2 for 28 days
u	Basic susceptibility to infection	~normal(0.09, 0.02)	Determines basic reproduction number R <sub>0</sub>
death_mean	Mean delay in days from start of infectious period to death	~normal(15, 2)	Delay is assumed to follow a gamma distribution with shape parameter 2.2. Prior and shape of distribution informed by analysis of CO-CIN data (66).



#### Parameters for VOC 202012/01 strain

Parameter	Description	Prior distribution	Notes
v2_when	Introduction date of VOC 202012/01 in days after 1 January 2020	~uniform(144, 365)	On this date, ten random individuals contract VOC 202012/01
v2_hosp_rlo	Relative log-odds of hospitalisation for VOC 202012/01, compared to preexisting variants	~normal(0, 0.1)	Vague prior
v2_icu_rlo	Relative log-odds of ICU admission for VOC 202012/01, compared to preexisting variants	~normal(0, 0.1)	Vague prior
v2_cfr_rlo	Relative log-odds of death for VOC 202012/01, compared to preexisting variants	~normal(0, 0.1)	Vague prior





When fitting deaths, hospital admissions, hospital bed occupancy and ICU bed occupancy, we used a negative binomial likelihood with a fitted size parameter for each series and region. For seroprevalence and PCR prevalence, we used a skew-normal likelihood for each data point fitted to produce the same mean and 95% confidence interval as was reported for the data, and took the expected value of the model prediction over the date range during which the prevalence was measured. For fitting to VOC 202012/01 relative frequency over time in the three heavily affected NHS England regions, we used a beta-binomial likelihood with the daily proportion of detected samples that were VOC 202012/01 and a fitted dispersion parameter.







## Mechanistic hypotheses for the rapid spread



We tested five hypotheses to explain Alpha's increased growth rate...



Immune escape

1.00

0.75

## Mechanistic hypotheses for the rapid spread



We tested five hypotheses to explain Alpha's increased growth rate...

### Table S4.

Model comparison for dynamic transmission models.

Hypothesis	DIC	Predictive deviance	ΔDIC	ΔΡD	Rank
Increased transmissibility	16246	6872	4	0	1
Increased duration of infectiousness	16242	8188	0	1316	2
Immune escape	19988	9314	3747	2442	4
Increased susceptibility in children	16385	8056	144	1184	3
Shorter generation time	17205	58373	963	51501	5
Combined	16295	18141	53	11269	_

### Projections for vaccination and NPIs





N G Davies, S Abbott, R C Barnard, C I Jarvis, A J Kucharski, J Munday, C AB Pearson, T W Russell, D C Tully, A D Washburne, T Wenseleers, A Gimma, W Waites, K LM Wong, K van Zandvoort, J D Silverman, K Diaz-Ordaz, R Keogh, R M Eggo, S Funk, M Jit, K E Atkins, W J Edmunds, CMMID COVID-19 Working Group. 2021. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. *Science* 372: eabg3055.





Coauthors: especially Rosanna Barnard, John Edmunds, Mark Jit, Rosalind Eggo, and the CMMID COVID-19 Working Group

Funders: the National Institute for Health and Care Research UK; Medical Research Council UK; UK Research and Innovation – Research England

Thank you for your attention!